Physician profile
Caisson Hogue
NPI 1437230612
$3,594.45
in general payments reported to CMS, 2019-2025
39 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $440 · 2021: $689 · 2022: $817 · 2023: $650 · 2024: $469 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.43 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $454.83 | 2020-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $171.56 | 2019-2022 | |
| Pfizer INC. | $162.50 | 2019-2024 | |
| Amgen INC. | $157.70 | 2019-2025 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $149.01 | 2020-2024 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $120.20 | 2020-2023 | Farxiga |
| Boston Scientific Corporation | $115.24 | 2019-2023 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Glaxosmithkline, LLC. | $114.13 | 2019-2023 | Trelegy Ellipta, Shingrix, Fluarix Quadrivalent |
| Jazz Pharmaceuticals INC. | $109.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $99.49 | 2019-2024 | |
| Astellas Pharma US INC | $95.97 | 2019-2024 | Myrbetriq, Veozah |
| Novo Nordisk INC | $91.50 | 2021-2024 | Rybelsus, Ozempic |
| Eisai INC. | $70.34 | 2020-2022 | |
| Allergan, INC. | $66.47 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caisson Hogue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.